display Latest news from Yale Cancer Center/Smilow Cancer Hospital on Å·ÃÀ¼«Æ· en-us Copyright 2024 Å·ÃÀ¼«Æ· 115 31 / /images/newswise-logo-rss.gif /articles/study-reveals-disparities-in-colorectal-cancer-screening/?sc=rsin /articles/study-reveals-disparities-in-colorectal-cancer-screening/?sc=rsin Thu, 03 Oct 2024 11:05:23 EST Significantly more younger people underwent colorectal cancer screening after the recommended age to begin such screening was lowered, Yale researchers report. In a new study of 10 million insured people aged 45 to 49, researchers found that a recommendation by the United States Preventative Services Task Force to drop the age for starting colorectal cancer screening by five years to age 45 was highly effective -- tripling the rate of screening overall -- but the magnitude of increase was significantly smaller for low-income and rural populations. Yale Cancer Center/Smilow Cancer Hospital /articles/yale-cancer-center-expert-available-to-discuss-new-american-cancer-society-report-revealing-higher-rates-of-early-onset-breast-cancer-and-disparities-in-underserved-populations/?sc=rsin /articles/yale-cancer-center-expert-available-to-discuss-new-american-cancer-society-report-revealing-higher-rates-of-early-onset-breast-cancer-and-disparities-in-underserved-populations/?sc=rsin Wed, 02 Oct 2024 12:05:56 EST Yale Cancer Center/Smilow Cancer Hospital /articles/new-barcode-technology-could-help-diagnose-cancer-more-precisely/?sc=rsin /articles/new-barcode-technology-could-help-diagnose-cancer-more-precisely/?sc=rsin Mon, 30 Sep 2024 11:05:51 EST A new pathology tool created at Yale harnesses barcode technology and shows potential for use in cancer diagnoses. The technology, Patho-DBiT (pathology-compatible deterministic barcoding in tissue), was discussed in a new study that published Sept. 30 in the journal Cell. Co-corresponding author Dr. Mina Xu, a Yale Cancer Center (YCC) member, professor of pathology at Yale School of Medicine (YSM), and the YSM director of hematopathology, shared her enthusiasm for the new tool. Yale Cancer Center/Smilow Cancer Hospital /articles/is-comprehensive-genetic-testing-worth-it-for-cancer-patients/?sc=rsin /articles/is-comprehensive-genetic-testing-worth-it-for-cancer-patients/?sc=rsin Tue, 24 Sep 2024 12:05:49 EST Comprehensive gene panel testing, one of the exciting new tools in cancer diagnostics, warrants greater scrutiny -- as does a federal program aimed at speeding up the review process for proposed new medical technologies. Those are conclusions of Yale medical experts who studied both and published a report in the Journal of the National Cancer Institute on Sept. Yale Cancer Center/Smilow Cancer Hospital /articles/advanced-3d-mammography-detects-more-breast-cancers-fewer-false-positives/?sc=rsin /articles/advanced-3d-mammography-detects-more-breast-cancers-fewer-false-positives/?sc=rsin Tue, 17 Sep 2024 11:05:06 EST The newer, 3D form of breast screening, known as digital breast tomosynthesis (DBT), is more effective at detecting breast cancer than traditional 2D digital mammography (DM). That's the conclusion of an analysis of 13 years' worth of screening data conducted by Yale Cancer Center researchers. Yale Cancer Center/Smilow Cancer Hospital /articles/botanical-medicine-reduces-rectal-cancer-treatment-side-effects-that-can-sideline-surgeries/?sc=rsin /articles/botanical-medicine-reduces-rectal-cancer-treatment-side-effects-that-can-sideline-surgeries/?sc=rsin Fri, 09 Aug 2024 17:05:04 EST Ancient Chinese traditional medicine significantly reduces the side effects of rectal cancer treatments that, in some patients, can be so toxic that treatment must be paused, or stopped, which diminishes its effectiveness. Yale Cancer Center/Smilow Cancer Hospital /articles/treatment-for-recurrent-uterine-cancer-advances-to-next-research-phase/?sc=rsin /articles/treatment-for-recurrent-uterine-cancer-advances-to-next-research-phase/?sc=rsin Wed, 31 Jul 2024 16:05:40 EST The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a phase III trial. Yale Cancer Center/Smilow Cancer Hospital /articles/yale-new-haven-hospital-nationally-ranked-in-11-specialties-by-u-s-news-world-report/?sc=rsin /articles/yale-new-haven-hospital-nationally-ranked-in-11-specialties-by-u-s-news-world-report/?sc=rsin Wed, 17 Jul 2024 09:05:45 EST In addition to earning the sixth spot nationally in Psychiatry, Yale New Haven Hospital ranked well in Obstetrics and Gynecology (#19), Otolaryngology (Ear Nose and Throat) (#27), Geriatrics (#28), Diabetes and Endocrinology (#29) Pulmonology and Lung Surgery (#31), Urology (#31), Heart and Heart Surgery (#43) Cancer (#45), Neurology and Neurosurgery (#48) and Gastroenterology and GI Surgery (#50). Yale Cancer Center/Smilow Cancer Hospital /articles/yale-scientists-develop-potential-stealth-cancer-therapy/?sc=rsin /articles/yale-scientists-develop-potential-stealth-cancer-therapy/?sc=rsin Mon, 15 Jul 2024 15:05:53 EST Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at the Yale School of Medicine (YSM). Yale Cancer Center/Smilow Cancer Hospital /articles/chemotherapy-before-surgery-benefits-some-patients-with-pancreatic-cancer/?sc=rsin /articles/chemotherapy-before-surgery-benefits-some-patients-with-pancreatic-cancer/?sc=rsin Thu, 20 Jun 2024 13:05:58 EST Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a new study from researchers at Yale Cancer Center (YCC) and Yale School of Medicine. The study, published June 20 in JAMA Oncology, included patients with pancreatic ductal adenocarcinoma (PDAC), which accounts for 90% of pancreatic cancers. Yale Cancer Center/Smilow Cancer Hospital /articles/promising-new-treatment-for-patients-with-hr-her-2-negative-metastatic-breast-cancer/?sc=rsin /articles/promising-new-treatment-for-patients-with-hr-her-2-negative-metastatic-breast-cancer/?sc=rsin Thu, 30 May 2024 15:05:56 EST New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer. Yale Cancer Center/Smilow Cancer Hospital /articles/arc-9-a-randomized-study-to-evaluate-etrumadenant-based-treatment-combinations-in-previously-treated-metastatic-colorectal-cancer-mcrc/?sc=rsin /articles/arc-9-a-randomized-study-to-evaluate-etrumadenant-based-treatment-combinations-in-previously-treated-metastatic-colorectal-cancer-mcrc/?sc=rsin Wed, 29 May 2024 21:05:40 EST Yale Cancer Center/Smilow Cancer Hospital /articles/a-phase-1-dose-expansion-study-of-a-first-in-class-kat6-inhibitor-pf-07248144-in-patients-with-advanced-or-metastatic-er-her2-breast-cancer/?sc=rsin /articles/a-phase-1-dose-expansion-study-of-a-first-in-class-kat6-inhibitor-pf-07248144-in-patients-with-advanced-or-metastatic-er-her2-breast-cancer/?sc=rsin Wed, 29 May 2024 21:05:37 EST Yale Cancer Center/Smilow Cancer Hospital /articles/arv-766-a-proteolysis-targeting-chimera-protac-androgen-receptor-ar-degrader-in-metastatic-castration-resistant-prostate-cancer-mcrpc-initial-results-of-a-phase-12-study/?sc=rsin /articles/arv-766-a-proteolysis-targeting-chimera-protac-androgen-receptor-ar-degrader-in-metastatic-castration-resistant-prostate-cancer-mcrpc-initial-results-of-a-phase-12-study/?sc=rsin Wed, 29 May 2024 21:05:23 EST Yale Cancer Center/Smilow Cancer Hospital /articles/a-promising-new-targeted-therapy-for-patients-with-metastatic-prostate-cancer-with-therapy-resistant-mutations/?sc=rsin /articles/a-promising-new-targeted-therapy-for-patients-with-metastatic-prostate-cancer-with-therapy-resistant-mutations/?sc=rsin Wed, 29 May 2024 11:05:55 EST Testosterone fuels the growth of prostate cancer. The target of testosterone is the androgen receptor. Metastatic prostate cancer is treated by reducing levels of testosterone, and despite initial responses to treatment, nearly all patients become resistant to androgen deprivation therapy. Yale Cancer Center/Smilow Cancer Hospital /articles/reducing-radiation-after-surgery-prolongs-survival-for-some-patients-with-hpv-related-throat-cancer/?sc=rsin /articles/reducing-radiation-after-surgery-prolongs-survival-for-some-patients-with-hpv-related-throat-cancer/?sc=rsin Wed, 29 May 2024 11:05:48 EST Patients being treated for HPV-related oropharynx cancer might need less radiation therapy typically given post-surgery, according to a new study. Yale Cancer Center/Smilow Cancer Hospital /articles/new-survival-data-from-a-lung-cancer-study-to-be-revealed-by-yale-cancer-center-expert-at-international-conference/?sc=rsin /articles/new-survival-data-from-a-lung-cancer-study-to-be-revealed-by-yale-cancer-center-expert-at-international-conference/?sc=rsin Fri, 24 May 2024 11:05:45 EST "The COAST study, which we began five years ago, involves patients who get chemotherapy and radiation therapy for lung cancer. And now we know that we can improve the outcome with a drug called durvalumab," explained Dr. Herbst, who will present the findings at ASCO. Yale Cancer Center/Smilow Cancer Hospital /articles/development-and-validation-of-rsclin-n-tool-for-hormone-receptor-positive-hr-her2-negative-her2-node-positive-breast-cancer/?sc=rsin /articles/development-and-validation-of-rsclin-n-tool-for-hormone-receptor-positive-hr-her2-negative-her2-node-positive-breast-cancer/?sc=rsin Tue, 21 May 2024 21:05:23 EST Yale Cancer Center/Smilow Cancer Hospital /articles/oncologists-should-re-evaluate-cancer-treatments-near-end-of-life/?sc=rsin /articles/oncologists-should-re-evaluate-cancer-treatments-near-end-of-life/?sc=rsin Thu, 16 May 2024 11:05:40 EST The study, which joins a growing body of research on end-of-life cancer treatment, published May 16 in JAMA Oncology. Yale Cancer Center/Smilow Cancer Hospital /articles/new-research-and-treatment-advances-from-yale-cancer-center-to-be-presented-at-the-world-s-largest-cancer-research-conference2/?sc=rsin /articles/new-research-and-treatment-advances-from-yale-cancer-center-to-be-presented-at-the-world-s-largest-cancer-research-conference2/?sc=rsin Mon, 13 May 2024 12:05:13 EST Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. Yale Cancer Center/Smilow Cancer Hospital